138 related articles for article (PubMed ID: 33073957)
21. Down-regulation of microRNA-26a and up-regulation of microRNA-27a contributes to aggressive progression of human osteosarcoma.
Taheriazam A; Bahador R; Karbasy SH; Jamshidi SM; Torkaman A; Yahaghi E; Shakeri M
Diagn Pathol; 2015 Sep; 10():166. PubMed ID: 26377680
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of miR-130b expression level and down-regulation of miR-218 serve as potential biomarker in the early detection of human osteosarcoma.
Taheriazam A; Talaei AJ; Jamshidi M; Shakeri M; Khoshbakht S; Yahaghi E; Shokrani M
Diagn Pathol; 2015 Oct; 10():184. PubMed ID: 26446495
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
Liu W; Zhao X; Zhang YJ; Fang GW; Xue Y
J Int Med Res; 2018 Mar; 46(3):975-983. PubMed ID: 29115164
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA34a is associated with chemotherapy resistance, metastasis, recurrence, survival, and prognosis in patient with osteosarcoma.
Lian H; Zhou Y; Sun Z; Liu K
Medicine (Baltimore); 2022 Sep; 101(38):e30722. PubMed ID: 36197268
[TBL] [Abstract][Full Text] [Related]
25. Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway.
Liu Q; Yang G; Qian Y
Mol Carcinog; 2017 Apr; 56(4):1312-1321. PubMed ID: 27859625
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway.
Jia F; Zhang Z; Zhang X
J Cell Biochem; 2019 Apr; 120(4):6420-6430. PubMed ID: 30484892
[TBL] [Abstract][Full Text] [Related]
27. Identification of plasma microRNA-22 as a marker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
Diao ZB; Sun TX; Zong Y; Lin BC; Xia YS
J Int Med Res; 2020 Dec; 48(12):300060520967818. PubMed ID: 33284712
[TBL] [Abstract][Full Text] [Related]
28. MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting BCL7A.
Dai J; Lu L; Kang L; Zhang J
Hum Cell; 2021 Mar; 34(2):624-633. PubMed ID: 33415690
[TBL] [Abstract][Full Text] [Related]
29. MiR-199b-5p promotes malignant progression of osteosarcoma by regulating HER2.
Chen Z; Zhao G; Zhang Y; Ma Y; Ding Y; Xu N
J BUON; 2018; 23(6):1816-1824. PubMed ID: 30610808
[TBL] [Abstract][Full Text] [Related]
30. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.
Ma W; Zhang X; Chai J; Chen P; Ren P; Gong M
Tumour Biol; 2014 Dec; 35(12):12467-72. PubMed ID: 25185654
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic effect of serum miR-139-5p as an indicator in osteosarcoma.
Zhou L; Ma X; Yue J; Chen T; Wang XY; Wang ZW; Pan J; Lin Y
Cancer Biomark; 2018; 23(4):561-567. PubMed ID: 30347602
[TBL] [Abstract][Full Text] [Related]
32. LncRNA ODRUL regulates progression of osteosarcoma by regulating IL-6 via sponging miR-6874-3p.
Zhan T; Zhu K; Hu J; Ma X; Zhu Y; Zhang C
Exp Cell Res; 2022 Mar; 412(2):113050. PubMed ID: 35114192
[TBL] [Abstract][Full Text] [Related]
33. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.
Wang D; Tang L; Wu H; Wang K; Gu D
IUBMB Life; 2018 May; 70(5):411-419. PubMed ID: 29573114
[TBL] [Abstract][Full Text] [Related]
34. Lupeol inhibits osteosarcoma progression by up-regulation of HMGA2 via regulating miR-212-3p.
Zhong J; He C; Xu F; Xu X; Liu L; Xu M; Guo Z; Wang Y; Liao J; Li Y
J Orthop Surg Res; 2020 Sep; 15(1):374. PubMed ID: 32883329
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Molecular Analysis of Pathologic Fracture-associated Osteosarcoma: MicroRNA profile Is Different and Correlates with Prognosis.
Lozano Calderón SA; Garbutt C; Kim J; Lietz CE; Chen YL; Bernstein K; Chebib I; Nielsen GP; Deshpande V; Rubio R; Wang YE; Quackenbush J; Delaney T; Raskin K; Schwab J; Cote G; Spentzos D
Clin Orthop Relat Res; 2019 Sep; 477(9):2114-2126. PubMed ID: 31389890
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients.
Shi L; Xie C; Zhu J; Chen X
Ann Diagn Pathol; 2020 Jun; 46():151488. PubMed ID: 32172218
[TBL] [Abstract][Full Text] [Related]
37. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma.
Allen-Rhoades W; Kurenbekova L; Satterfield L; Parikh N; Fuja D; Shuck RL; Rainusso N; Trucco M; Barkauskas DA; Jo E; Ahern C; Hilsenbeck S; Donehower LA; Yustein JT
Cancer Med; 2015 Jul; 4(7):977-88. PubMed ID: 25784290
[TBL] [Abstract][Full Text] [Related]
38. miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.
Sun X; Dai G; Yu L; Hu Q; Chen J; Guo W
Sci Rep; 2018 Jan; 8(1):606. PubMed ID: 29330462
[TBL] [Abstract][Full Text] [Related]
39. By targeting TRAF6, miR-140-3p inhibits TGF-β1-induced human osteosarcoma epithelial-to-mesenchymal transition, migration, and invasion.
Guo Q; Zhang N; Liu S; Pang Z; Chen Z
Biotechnol Lett; 2020 Nov; 42(11):2123-2133. PubMed ID: 32562135
[TBL] [Abstract][Full Text] [Related]
40. Identification of circulating miR-663a as a potential biomarker for diagnosing osteosarcoma.
Huang C; Sun Y; Ma S; Vadamootoo AS; Wang L; Jin C
Pathol Res Pract; 2019 Jun; 215(6):152411. PubMed ID: 30987831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
